The Cancer Prevention Clinical Trials Network (CP-CTNet) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials. The goal is to identify safe and effective interventions in order to advance their further clinical development for cancer prevention.

Sue Siminski, Frontier Science CEO, serves as the Director for the CP-CTNet Data Management and Reporting Unit. Frontier Science provides data management, reporting, randomization, auditing, and site support services, as well as expertise on the creation of study-specific software systems. We have assisted the network in establishing centralized electronic data collection systems, and have developed a number of customized software solutions to propel the efforts of CP-CTNet.

In addition, Frontier Science works with the CP-CTNet Administrative and Coordinating Unit, in a partnership with the University of Wisconsin, to perform site auditing and assist the sites in establishing more robust quality management systems and efficient workflows.